<?xml version='1.0' encoding='utf-8'?>
<document id="25895965"><sentence text="Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors."><entity charOffset="127-137" id="DDI-PubMed.25895965.s1.e0" text="paclitaxel" /></sentence><sentence text="Trebananib is an anti-angiogenic peptibody under investigation in patients with advanced cancer"><entity charOffset="0-10" id="DDI-PubMed.25895965.s2.e0" text="Trebananib" /></sentence><sentence text=" This study evaluated the pharmacokinetic (PK) drug-drug interaction of paclitaxel and trebananib"><entity charOffset="72-82" id="DDI-PubMed.25895965.s3.e0" text="paclitaxel" /><entity charOffset="87-97" id="DDI-PubMed.25895965.s3.e1" text="trebananib" /><pair ddi="false" e1="DDI-PubMed.25895965.s3.e0" e2="DDI-PubMed.25895965.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25895965.s3.e0" e2="DDI-PubMed.25895965.s3.e1" /></sentence><sentence text="" /><sentence text="Patients with advanced solid tumors received weekly 80 mg/m(2) intravenous (IV) paclitaxel (3 weeks on/1 week off) with weekly 15 mg/kg IV trebananib starting at Week 2"><entity charOffset="80-90" id="DDI-PubMed.25895965.s5.e0" text="paclitaxel" /></sentence><sentence text=" Blood samples for PK analysis were collected at Week 1 (paclitaxel alone), Week 6 (paclitaxel and trebananib), and Week 8 (trebananib alone)"><entity charOffset="57-67" id="DDI-PubMed.25895965.s6.e0" text="paclitaxel" /><entity charOffset="84-94" id="DDI-PubMed.25895965.s6.e1" text="paclitaxel" /><entity charOffset="99-109" id="DDI-PubMed.25895965.s6.e2" text="trebananib" /><pair ddi="false" e1="DDI-PubMed.25895965.s6.e0" e2="DDI-PubMed.25895965.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25895965.s6.e0" e2="DDI-PubMed.25895965.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25895965.s6.e0" e2="DDI-PubMed.25895965.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25895965.s6.e1" e2="DDI-PubMed.25895965.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25895965.s6.e1" e2="DDI-PubMed.25895965.s6.e2" /></sentence><sentence text=" An absence of interaction was to be concluded if the 90 % confidence intervals (CI) for the differences in paclitaxel exposure fell within the 0"><entity charOffset="108-118" id="DDI-PubMed.25895965.s7.e0" text="paclitaxel" /></sentence><sentence text="80-1" /><sentence text="25 interval" /><sentence text="" /><sentence text="The primary study was conducted between 7/2012 and 10/2013" /><sentence text=" Thirty-five patients were enrolled and 34 received both treatments" /><sentence text=" Most patients were white (91 %) and female (59 %); mean age was 61 years" /><sentence text=" The most common tumor types were ovarian (32 %) and bladder (27 %), 71 % of patients had stage IV disease, and all had Eastern Cooperative Oncology Group (ECOG) scores of 0 or 1" /><sentence text=" PK parameter analysis was done on patients with evaluable PK data at both assessments (with and without concomitant therapy; n = 28)" /><sentence text=" The geometric least squares mean (GLSM) ratio (90 % CI) of paclitaxel AUCinf with and without trebananib was 1"><entity charOffset="60-70" id="DDI-PubMed.25895965.s16.e0" text="paclitaxel" /><entity charOffset="95-105" id="DDI-PubMed.25895965.s16.e1" text="trebananib" /><pair ddi="false" e1="DDI-PubMed.25895965.s16.e0" e2="DDI-PubMed.25895965.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25895965.s16.e0" e2="DDI-PubMed.25895965.s16.e1" /></sentence><sentence text="17 (1" /><sentence text="10, 1" /><sentence text="25)" /><sentence text=" The GLSM ratio (90 % CI) of trebananib AUCtau,ss with and without paclitaxel was 0"><entity charOffset="29-39" id="DDI-PubMed.25895965.s20.e0" text="trebananib" /><entity charOffset="67-77" id="DDI-PubMed.25895965.s20.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.25895965.s20.e0" e2="DDI-PubMed.25895965.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25895965.s20.e0" e2="DDI-PubMed.25895965.s20.e1" /></sentence><sentence text="92 (0" /><sentence text="87, 0" /><sentence text="97)" /><sentence text=" The most common adverse events were fatigue, local edema, peripheral edema, and nausea" /><sentence text="" /><sentence text="This study showed no evidence of clinically meaningful PK interaction between paclitaxel and trebananib"><entity charOffset="78-88" id="DDI-PubMed.25895965.s26.e0" text="paclitaxel" /><entity charOffset="93-103" id="DDI-PubMed.25895965.s26.e1" text="trebananib" /><pair ddi="false" e1="DDI-PubMed.25895965.s26.e0" e2="DDI-PubMed.25895965.s26.e0" /><pair ddi="false" e1="DDI-PubMed.25895965.s26.e0" e2="DDI-PubMed.25895965.s26.e1" /></sentence><sentence text="" /></document>